Journal
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 36, Issue 1, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2022.101742
Keywords
Rheumatoid arthritis; Precision medicine; Single-cell RNAseq; Spatial transcriptomics; Organoids
Categories
Funding
- National Institute of Arthritis and Musculoskeletal and Skin Diseases award [K08AR077037]
- Rheumatology Research Foundation Innovative Research award
- Burroughs Wellcome Fund Career Award for Medical Scientists
- BWH/BCH Joint Biology Consoritum [NIH P30 AR070253]
Ask authors/readers for more resources
Cellular profiling techniques have revealed novel pathogenic cell types and cellular heterogeneity in rheumatoid arthritis, offering opportunities for precision medicine. Efforts to identify predictive biomarkers and develop patient-derived organoid systems are crucial for translating discoveries into clinical practice.
Rheumatoid arthritis is an autoimmune disease that causes significant morbidity. Application of cellular profiling techniques such as single-cell transcriptomics and spatial transcriptomics has uncovered novel pathogenic cell types in RA joint tissues and revealed marked heterogeneity in the cellular composition among RA patients. Together, these insights provide exciting opportunities to translate discoveries into precision medicine in RA. The present review aims to highlight novel insights into RA pathology and discuss key steps needed to translate these discoveries into actionable changes in clinical practice. We review the efforts to identify surrogate biomarkers that could be used to predict RA synovial tissue phenotypes and the corresponding responses to therapy. Finally, we discuss the opportunity to develop novel patient-derived organoid systems as a platform for therapeutic target validation. (c) 2022 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available